NEW YORK, Sept. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

Amidst the ongoing Tesla (NASDAQ: TSLA) stock volatility, South Korean retail investors are rapidly pulling out of the equity in favor of cryptocurrencies.

PH gains from aerospace strength and acquisitions, but industrial weakness and currency headwinds weigh on results.

NEW YORK, Sept. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Lineage, Inc. (NASDAQ: LINE) common stock pursuant and/or traceable to the registration statement issued in connection with Lineage's July 2024 initial public offering (the “IPO”) of the important September 30, 2025 lead plaintiff deadline.

BROS' rapid expansion and strong comps fuel growth, but sustaining traffic momentum as competition heats up is the key test ahead.

Qualcomm stock slid 8.3% in a year as China trade woes, rising R&D costs and tough competition weigh on margins despite Snapdragon and auto gains.

Oracle (ORCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ENB's vast pipeline network and fee-based contracts help it generate steady cash flows despite oil and gas price swings.

ICUI faces an FDA recall of its Plum Duo Infusion System over software flaws, though devices remain in use, pending fixes.

XOM's outlook warns that net-zero targets are slipping as coal use rebounds and oil and gas demand stays strong through 2050.

TotalEnergies teams up with XING Mobility to advance immersion cooling battery systems for marine, energy storage and AI data centers.

BA's defense unit shines with a surging backlog and revenue growth, helping balance challenges in the commercial unit.

Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.

After reaching an important support level, S&T Bancorp, Inc. (STBA) could be a good stock pick from a technical perspective. STBA recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Puma Biotech (PBYI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

After losing some value lately, a hammer chart pattern has been formed for XOMA Royalty (XOMA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

After losing some value lately, a hammer chart pattern has been formed for Ascentage Pharma Group International - Unsponsored ADR (AAPG), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

The consensus price target hints at a 32.6% upside potential for ARKO (ARKO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 45.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.